The present research work describes the  improvement of  bioavailability of Isradipine through buccal delivery. Isradipine buccal tablets were prepared with β cyclodextrin which improved the photostability of the drug. Buccal formulations were evaluated for in vitro release, moisture absorption, mechanical properties, and bioadhesion, and optimized formulation was subjected for bioavailability studies in healthy human volunteers and compared with marketed tablet. The pharmacokinetic parameters Cmax, tmax and AUCo-t of test formulation were calculated and compared with the reference i.e., marketed product. It was observed from the study that the drug release from the test formulation could be sustained and it was concluded that the test formulation was able to sustain the drug release as compared to reference marketed product with 1.672 fold increase in extent of absorption i.e., AUC0-t.